{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:06:37Z","timestamp":1793113597414,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T00:00:00Z","timestamp":1636502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100008895","name":"Tertiary Education Trust Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008895","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012940","name":"Universit\u00e4tsklinikum T\u00fcbingen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100012940","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The occurrence of artemisinin resistance (ART)-associated polymorphism of <jats:italic>Plasmodium falciparum<\/jats:italic> K13-propeller (<jats:italic>pfk13<\/jats:italic>) gene before and after the introduction of artemisinin-based combination therapy (ACT) in two regions of Nigeria was investigated in this study. Regular surveillance is necessary to make a definite conclusion on the emergence and pattern of possible resistance to ART.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This cross-sectional study was carried out in the Southwestern and Southeastern geopolitical zones of Nigeria. A total of 150, 217, and 475 participants were enrolled for the study in the Southwest (2004_Group A), Southwest (2015_Group B), and southeast (2015_Group C), respectively. Blood samples were collected from the study participants for DNA extraction and a nested PCR for <jats:italic>P. falciparum<\/jats:italic> identification. Samples that were positive for <jats:italic>P. falciparum<\/jats:italic> were genotyped for the <jats:italic>pfk13<\/jats:italic> gene using the Sanger sequencing method. The single nucleotide polymorphisms were analysed using the Bioedit software.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 116, 125, and 83 samples were positive for <jats:italic>P. falciparum,<\/jats:italic> respectively for the samples collected from the Southwest (2004 and 2015) and southeast (2015). Parasite DNA samples collected from febrile children in 2004 (Group A; n\u2009=\u200971) and 2015 (Group B; n\u2009=\u200973) in Osogbo Western Nigeria and 2015_Group C (n\u2009=\u200936) in southeast Nigeria were sequenced successfully. This study did not observe mutations associated with the in vitro resistance in southeast Asia, such as Y493H, R539T, I543T, and C580Y. Two new polymorphisms V520A and V581I were observed in two samples collected in Osogbo, Southwest Nigeria. These two mutations occurred in the year 2004 (Group A) before the introduction of ACT. Six mutations were identified in 17% of the samples collected in southeast Nigeria. One of these mutations (D547G) was non-synonymous, while the remaining (V510V, R515R, Q613Q, E688E, and N458N) were synonymous. Also, one (2%) heterozygote allele was identified at codon 458 in the 2015 (Group C) samples.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>None of the mutations observed in this study were previously validated to be associated with ART resistance. These results, therefore, suggest that artemisinin is likely to remain highly effective in treating malaria in the study areas that are malarious zone.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12936-021-03968-9","type":"journal-article","created":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T11:04:48Z","timestamp":1636542288000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Absence of Plasmodium falciparum artemisinin resistance gene mutations eleven years after the adoption of artemisinin-based combination therapy in Nigeria"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5264-9256","authenticated-orcid":false,"given":"Moses","family":"Ikegbunam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnson A.","family":"Ojo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kossiwa","family":"Kokou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ugonna","family":"Morikwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chukwuemeka","family":"Nworu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chibuzo","family":"Uba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Esimone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thirumalaisamy P.","family":"Velavan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olusola","family":"Ojurongbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,11,10]]},"reference":[{"issue":"Suppl 1","key":"3968_CR1","first-page":"7","volume":"19","author":"WHO","year":"2014","unstructured":"WHO. Severe malaria. Trop Med Int Health. 2014;19(Suppl 1):7\u2013131.","journal-title":"Trop Med Int Health"},{"key":"3968_CR2","unstructured":"WHO. World Malaria Report 2016 [Internet]. Geneva, World Health Organization, 2016. http:\/\/www.who.int\/malaria\/publications\/world-malaria-report-2016\/report\/en\/. Accessed 7 Jul 2017."},{"key":"3968_CR3","doi-asserted-by":"publisher","first-page":"26","DOI":"10.3390\/tropicalmed4010026","volume":"4","author":"C Nsanzabana","year":"2019","unstructured":"Nsanzabana C. Resistance to artemisinin combination therapies (ACTs): do not forget the partner drug! Trop Med Infect Dis. 2019;4:26.","journal-title":"Trop Med Infect Dis"},{"key":"3968_CR4","doi-asserted-by":"publisher","first-page":"181","DOI":"10.4269\/ajtmh.2007.77.181","volume":"77","author":"F Nosten","year":"2007","unstructured":"Nosten F, White NJ. Artemisinin-based combination treatment of falciparum malaria. Am J Trop Med Hyg. 2007;77:181\u201392.","journal-title":"Am J Trop Med Hyg"},{"key":"3968_CR5","unstructured":"WHO. Withdrawal of oral artemisinin-based monotherapies [Internet]. Geneva, World Health Organization, 2017. https:\/\/www.who.int\/malaria\/areas\/treatment\/withdrawal_of_oral_artemisinin_based_monotherapies\/en\/. Accessed 17 Feb 2021."},{"key":"3968_CR6","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1186\/s12936-016-1392-5","volume":"15","author":"ST Thein","year":"2016","unstructured":"Thein ST, Sudhinaraset M, Khin HSS, McFarland W, Aung T. Who continues to stock oral artemisinin monotherapy? Results of a provider survey in Myanmar. Malar J. 2016;15:334.","journal-title":"Malar J"},{"key":"3968_CR7","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1056\/NEJMoa1314981","volume":"371","author":"EA Ashley","year":"2014","unstructured":"Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411\u201323.","journal-title":"N Engl J Med"},{"key":"3968_CR8","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1056\/NEJMc0805011","volume":"359","author":"H Noedl","year":"2008","unstructured":"Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, et al. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359:2619\u201320.","journal-title":"N Engl J Med"},{"key":"3968_CR9","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1056\/NEJMoa0808859","volume":"361","author":"AM Dondorp","year":"2009","unstructured":"Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455\u201367.","journal-title":"N Engl J Med"},{"key":"3968_CR10","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1128\/AAC.01868-12","volume":"57","author":"B Witkowski","year":"2013","unstructured":"Witkowski B, Khim N, Chim P, Kim S, Ke S, Kloeung N, et al. Reduced artemisinin susceptibility of Plasmodium falciparum ring stages in western Cambodia. Antimicrob Agents Chemother. 2013;57:914\u201323.","journal-title":"Antimicrob Agents Chemother"},{"key":"3968_CR11","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature12876","volume":"505","author":"F Ariey","year":"2014","unstructured":"Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois A-C, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50\u20135.","journal-title":"Nature"},{"key":"3968_CR12","unstructured":"WHO. Artemisinin resistance and artemisinin-based combination therapy efficacy: status report. Geneva, World Health Organization, 2018 [cited 2021 Feb 17]; https:\/\/apps.who.int\/iris\/handle\/10665\/274362. Accessed 17 Feb 2021."},{"key":"3968_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1051\/parasite\/2018021","volume":"25","author":"M Ouji","year":"2018","unstructured":"Ouji M, Augereau J-M, Paloque L, Benoit-Vical F. Plasmodium falciparum resistance to artemisinin-based combination therapies: a sword of Damocles in the path toward malaria elimination. Parasite. 2018;25:24.","journal-title":"Parasite"},{"key":"3968_CR14","first-page":"1352","volume":"211","author":"E Kamau","year":"2015","unstructured":"Kamau E, Campino S, Amenga-Etego L, Drury E, Ishengoma D, Johnson K, et al. K13-propeller polymorphisms in Plasmodium falciparum parasites from sub-Saharan Africa. J Infect Dis. 2015;211:1352\u20135.","journal-title":"J Infect Dis"},{"key":"3968_CR15","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1056\/NEJMoa1513137","volume":"374","author":"D M\u00e9nard","year":"2016","unstructured":"M\u00e9nard D, Khim N, Beghain J, Adegnika AA, Shafiul-Alam M, Amodu O, et al. A worldwide map of Plasmodium falciparum K13-propeller polymorphisms. N Engl J Med. 2016;374:2453\u201364.","journal-title":"N Engl J Med"},{"key":"3968_CR16","doi-asserted-by":"publisher","first-page":"2305062","DOI":"10.1155\/2018\/2305062","volume":"2018","author":"MA Oboh","year":"2018","unstructured":"Oboh MA, Ndiaye D, Antony HA, Badiane AS, Singh US, Ali NA, et al. Status of artemisinin resistance in malaria parasite Plasmodium falciparum from molecular analyses of the Kelch13 gene in Southwestern Nigeria. BioMed Res Int. 2018;2018:2305062.","journal-title":"BioMed Res Int"},{"key":"3968_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.9734\/IJTDH\/2017\/30914","volume":"21","author":"GS Wundermann","year":"2017","unstructured":"Wundermann GS, Osiki AA. Currently observed trend in the resistance of malaria to artemisinin based combination therapy in Nigeria\u2014a report of 5 cases. Int J Trop Dis Health. 2017;21:1\u20135.","journal-title":"Int J Trop Dis Health"},{"key":"3968_CR18","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1590\/0037-8682-0098-2013","volume":"46","author":"NA Ajayi","year":"2013","unstructured":"Ajayi NA, Ukwaja KN, Ajayi NA, Ukwaja KN. Possible artemisinin-based combination therapy-resistant malaria in Nigeria: a report of three cases. Rev Soc Brasil Med Trop. 2013;46:525\u20137.","journal-title":"Rev Soc Brasil Med Trop"},{"key":"3968_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/1475-2875-6-41","volume":"6","author":"O Ojurongbe","year":"2007","unstructured":"Ojurongbe O, Ogungbamigbe TO, Fagbenro-Beyioku AF, Fendel R, Kremsner PG, Kun JF. Rapid detection of Pfcrt and Pfmdr1 mutations in Plasmodium falciparum isolates by FRET and in vivo response to chloroquine among children from Osogbo. Nigeria Malar J. 2007;6:41.","journal-title":"Nigeria Malar J"},{"key":"3968_CR20","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/s12936-019-2977-6","volume":"18","author":"MN Ikegbunam","year":"2019","unstructured":"Ikegbunam MN, Nkonganyi CN, Thomas BN, Esimone CO, Velavan TP, Ojurongbe O. Analysis of Plasmodium falciparum Pfcrt and Pfmdr1 genes in parasite isolates from asymptomatic individuals in Southeast Nigeria 11 years after withdrawal of chloroquine. Malar J. 2019;18:343.","journal-title":"Malar J"},{"key":"3968_CR21","volume-title":"National malaria and vector control division","author":"Federal Ministry of Health","year":"2005","unstructured":"Federal Ministry of Health. National malaria and vector control division. Abuja: National Antimalarial Treatment Policy; 2005."},{"key":"3968_CR22","doi-asserted-by":"publisher","first-page":"2025858","DOI":"10.1155\/2018\/2025858","volume":"2018","author":"RN Okoro","year":"2018","unstructured":"Okoro RN, Jamiu MO. The cross-sectional evaluation of the use of artemisinin-based combination therapy for treatment of malaria infection at a tertiary hospital in Nigeria. J Trop Med. 2018;2018:2025858.","journal-title":"J Trop Med"},{"key":"3968_CR23","first-page":"112","volume":"8","author":"MK Omole","year":"2010","unstructured":"Omole MK, Onademuren OT. A survey of antimalarial drug use practices among urban dwellers of Abeokuta in south west Nigeria. Nigerian J Pharm Res. 2010;8:112\u201321.","journal-title":"Nigerian J Pharm Res"},{"key":"3968_CR24","doi-asserted-by":"publisher","first-page":"390","DOI":"10.4236\/ojpm.2012.23056","volume":"2","author":"N Harrison","year":"2012","unstructured":"Harrison N, Olufunlayo T, Agomo C. Utilization of the current national antimalarial treatment guidelines among doctors in army hospitals in Lagos. Nigeria Open J Prev Med. 2012;2:390\u20133.","journal-title":"Nigeria Open J Prev Med"},{"key":"3968_CR25","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/infdis\/jiu467","volume":"211","author":"SM Taylor","year":"2015","unstructured":"Taylor SM, Parobek CM, DeConti DK, Kayentao K, Coulibaly SO, Greenwood BM, et al. Absence of putative artemisinin resistance mutations among Plasmodium falciparum in Sub-Saharan Africa: a molecular epidemiologic study. J Infect Dis. 2015;211:680\u20138.","journal-title":"J Infect Dis"},{"key":"3968_CR26","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/bs.enz.2017.03.006","volume":"41","author":"Y Wang","year":"2017","unstructured":"Wang Y, Zheng Y, Beal PA. Adenosine deaminases that act on RNA (ADARs). Enzymes. 2017;41:215\u201368.","journal-title":"Enzymes"},{"key":"3968_CR27","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/s12936-019-2701-6","volume":"18","author":"M Ocan","year":"2019","unstructured":"Ocan M, Akena D, Nsobya S, Kamya MR, Senono R, Kinengyere AA, et al. K13-propeller gene polymorphisms in Plasmodium falciparum parasite population in malaria affected countries: a systematic review of prevalence and risk factors. Malar J. 2019;18:60.","journal-title":"Malar J"},{"key":"3968_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-018-1207-3","author":"WWARN K13 Genotype-Phenotype Study Group","year":"2019","unstructured":"WWARN K13 Genotype-Phenotype Study Group. Association of mutations in the Plasmodium falciparum Kelch13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatments\u2014a WWARN individual patient data meta-analysis. BMC Med. 2019. https:\/\/doi.org\/10.1186\/s12916-018-1207-3.","journal-title":"BMC Med"},{"key":"3968_CR29","doi-asserted-by":"publisher","first-page":"e105690","DOI":"10.1371\/journal.pone.0105690","volume":"8","author":"MD Conrad","year":"2014","unstructured":"Conrad MD, Bigira V, Kapisi J, Muhindo M, Kamya M. Polymorphisms in K13 and falcipain-2 associated with artemisinin resistance are not prevalent in Plasmodium falciparum isolated from Ugandan children. PLoS ONE. 2014;8:e105690.","journal-title":"PLoS ONE"},{"key":"3968_CR30","doi-asserted-by":"publisher","first-page":"5061","DOI":"10.1128\/AAC.00921-15","volume":"59","author":"RA Cooper","year":"2015","unstructured":"Cooper RA, Conrad MD, Watson QD, Huezo SJ, Ninsiima H, Tumwebaze P, et al. Lack of artemisinin resistance in Plasmodium falciparum in Uganda based on parasitological and molecular assays. Antimicrob Agents Chemother. 2015;59:5061\u20134.","journal-title":"Antimicrob Agents Chemother"},{"key":"3968_CR31","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3201\/eid2701.203527","volume":"27","author":"C Bergmann","year":"2021","unstructured":"Bergmann C, van Loon W, Habarugira F, Tacoli C, J\u00e4ger JC, Savelsberg D, et al. Increase in Kelch 13polymorphisms in Plasmodium falciparum, Southern Rwanda. Emerg Infect Dis. 2021;27:294\u20136.","journal-title":"Emerg Infect Dis"},{"key":"3968_CR32","doi-asserted-by":"publisher","first-page":"649","DOI":"10.4269\/ajtmh.18-0115","volume":"99","author":"JC Ebenebe","year":"2018","unstructured":"Ebenebe JC, Ntadom G, Ambe J, Wammanda R, Jiya N, Finomo F, et al. Efficacy of artemisinin-based combination treatments of uncomplicated falciparum malaria in under-five-year-old Nigerian children ten years following adoption as first-line antimalarials. Am J Trop Med Hyg. 2018;99:649\u201364.","journal-title":"Am J Trop Med Hyg"},{"key":"3968_CR33","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1056\/NEJMc1612765","volume":"376","author":"F Lu","year":"2017","unstructured":"Lu F, Culleton R, Zhang M, Ramaprasad A, von Seidlein L, Zhou H, et al. Emergence of indigenous artemisinin-resistant Plasmodium falciparum in Africa. N Engl J Med. 2017;376:991\u20133.","journal-title":"N Engl J Med"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03968-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-021-03968-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-021-03968-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,10]],"date-time":"2021-11-10T11:10:57Z","timestamp":1636542657000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-021-03968-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,10]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["3968"],"URL":"https:\/\/doi.org\/10.1186\/s12936-021-03968-9","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,10]]},"assertion":[{"value":"12 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved ethically by the Ethical Review Committee of the Osun State Ministry of Health, Osogbo (OSHREC\/PRS\/569\u00a0T\/130) and the Ethics Review Board, University of Nigeria Teaching Hospital, Enugu, South Eastern Nigeria (approval number: NHREC\/05\/01\/2008B-FWA00002458-IRB00002323).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest. The funders had no role in the study's design; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results\".","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"434"}}